

Please add new claims 9-13 as follows:

Subj A2
9. [New] The method of claim 3, wherein said at least one compound is administered by way of eye drop or systemically.

10. [New] The method of claim 3, wherein the compound is selected from the group consisting of Gd³⁺, agonists of Gd³⁺ on neural cells, pyrazine-carboxamides, aminoglycoside antibiotics, netilmycin, sodium channel blockers, calcium channel blockers, potassium channel blockers, calcium ions, protons, aluminum ions, tubocurarine, halothane and other inhalational anaesthetics, quinine, integrin-blocking peptides and antibodies, cisplatin, tarantula spider venom, and colchicin.

11. [New] A composition for the treatment of glaucoma which comprises at least one compound which blocks stretch activated channels of eye retinal ganglion cells or other pressure sensitive mechanisms of retinal ganglion cells, said at least one compound being in association with one or more pharmaceutically acceptable carriers or excipients.

12. [New] The method of claim 11, wherein said at least one compound is administered by way of eye drop or systemically.

13. [New] The method of claim 11, wherein the compound is selected from the group consisting of Gd³⁺, agonists of Gd³⁺ on neural cells, pyrazine-carboxamides, aminoglycoside antibiotics, netilmycin, sodium channel blockers, calcium channel blockers, potassium channel blockers, calcium ions, protons, aluminum ions, tubocurarine, halothane and other inhalational anaesthetics, quinine, integrin-blocking peptides and antibodies, cisplatin, tarantula spider venom, and colchicin.

REMARKS

Examination on the merits of claim 3 as amended and new claims 9-13 is respectfully requested. Support for the newly added claims can be found throughout the specification and within the originally filed claims. For example, support for the amendments and newly added claims can be found at least at pages 3, and 7-9.